AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Anti-Müllerian Hormone in Breast Cancer Clinical Practice

Recruitingn/aAges 20 Years - 55 YearsFemaleMasaryk Memorial Cancer Institute
💬

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate serum anti-Müllerian hormone (AMH) levels and complementary hormonal parameters, including follicle-stimulating hormone (FSH), estradiol, thyroid-stimulating hormone (TSH), and free thyroxine (fT4), in women with breast cancer and healthy female controls. The study will generate preliminary real-world data on AMH and related hormonal parameters and assess the feasibility of implementing AMH testing into routine clinical practice.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Women aged 20-55 years. * Patients with a diagnosis of breast cancer at any of the specified stages of treatment or follow-up, or healthy female volunteers. * Blood sampling as part of routine clinical care (breast cancer patients) or willingness to undergo a single blood draw (healthy volunteers). Exclusion Criteria: * Inability or unwillingness to participate in the study.
💊

What it tests

  • Not listed
📍

Where

1 site
Masaryk Memorial Cancer Institute
Brno, Czechia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy